Click here to see slides

Table of Contents

»Mean steady-state saquinavir plasma concentration in HIV-infected subjects Study NV15107
»Exposure–response (2 parameter Emax model) for saquinavir-SGCStudy NV15107
»Effect of saquinavir-SGC on the pharmacokinetics of co-administered drugs
»Effect of co-administered drugs on saquinavir pharmacokinetics
»Percentage of individuals experiencing clinical adverse eventsa in studies NV15182 and NV15355
»Percentage of individuals with marked laboratorya abnormalities in studies NV15182 and NV15355
»Proportion of subjects <400 copies/mL Study NV15355
»Proportion of subjects <50 copies/mL Study NV15355
»HIV-1 RNA and CD4 changes in value over time for standard population SUN study
»Virological response after 24 weeks of the CHEESE study
»CD4+ T-cell response after 24 weeks of the CHEESE study
»Proportion below limit of quantification UltraSensitive (<50 copies/mL); ITT
»Proportion below limit of quantification UltraSensitive (<50 copies/mL); OT
»Proportion below limit of quantification Patients crossed over to SQV+NFV+2nRTIs; OT
»TIBID Study: Propotion of subjects <400 copies/mL; OT & ITT
»TIBID Study: Proportion of subjects <50 copies/mL; OT & ITT
»Proportion of subjects <400 copies/mL (Amplicor) and <50 copies/mL (UltraSensitive) NV15545 Part 1, All Patients, ITT
»Mean nonfasting serum triglyceride M61018 (TIDBID)
»Mean nonfasting serum triglyceride SWITCH study
»Mean fasting serum triglyceride in healthy volunteers